
Bellicum Pharmaceuticals
A clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders.
Market cap
$787k
Enterprise value
($45m)
Share price
$0.07 BLCM
Authorizing premium user...